The long term objective is to improve the dosimetry of bone during radionuclide cancer therapy through enhancements and use of small-scale dosimetry techniques. Radionuclide cancer therapy includes treatment with radiolabeled antibodies, radiolabeled compounds, and radionuclides. Approximately 125,000 cancer patients per year develop bone metastases in the U.S., and the severe pain, immobility, anorexia, and anxiety significantly impair the quality of life of these patients. Alternate radiopharmaceuticals are being studied for the treatment of primary and metastatic bone lesions that are less toxic than external beam radiotherapy. However, absorbed dose calculations to bone tissues require a degree of accuracy and an estimate of the associated uncertainties to carry out clinical studies with confidence. This is in order to correlate dose or dose distributions to bone tissues with toxicity and/or tumor control. The hypotheses of the proposed work are that: a) The existing bone dosimetric methods for use in radionuclide therapy can be enhanced by using small-scale dosimetry techniques that take into consideration the localized bone morphological characteristics and radionuclide distribution in bone tissues. b) These improvements will lead to a better understanding of normal-tissue toxicity and effectiveness of tumor control in clinical trials. To test these hypotheses, small-scale dosimetry techniques based on beta and alpha Monte Carlo transport will be used for the assessment of absorbed doses in localized bone regions. The dosimetric models will consider the morphological information obtained using histological images of human bones. Experiments using micro-thermoluminescent dosimeters will be carried out to validate the model predictions. A comprehensive study will be carried out to assess localized doses based on sources and target tissues using human bone specimens. Moreover, a digital autoradiography system for the quantitative spatial correlation of activity distributions in bone tissues will be assembled. This system will be used to assess the fractional activity distribution in animal models. Radionuclide distribution data from animal experiments will be used for extrapolation and correlation to human bones based on a comparative study of morphological and physiological parameters. Findings will allow experimental results obtained from these animals to be extrapolated to human bone with more confidence. Finally, a set of recommendations for the localized dosimetry of bone based on bone type and lesion will be established.

National Institute of Health (NIH)
National Cancer Institute (NCI)
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
Application #
Study Section
Radiation Study Section (RAD)
Program Officer
Stone, Helen B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
McLendon, Roger E; Akabani, Gamal; Friedman, Henry S et al. (2007) Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol 34:405-13
Akabani, Gamal; Reardon, David A; Coleman, R Edward et al. (2005) Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46:1042-51
Rizzieri, David A; Akabani, Gamal; Zalutsky, Michael R et al. (2004) Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 104:642-8
Akabani, Gamal; Kennel, Stephen J; Zalutsky, Michael R (2003) Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. J Nucl Med 44:792-805
Carlin, Sean; Akabani, Gamal; Zalutsky, Michael R (2003) In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med 44:1827-38
Akabani, Gamal; McLendon, Roger E; Bigner, Darrell D et al. (2002) Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. Int J Radiat Oncol Biol Phys 54:1259-75
Larsen, R H; Akabani, G; Welsh, P et al. (1998) The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res 149:155-62
Akabani, G; Zalutsky, M R (1997) Microdosimetry of astatine-211 using histological images: application to bone marrow. Radiat Res 148:599-607